Lifecore Biomedical to Report Financial Results for Second Quarter of Fiscal 2025 on January 2, 2025
19 déc. 2024 16h05 HE
|
Lifecore Biomedical, Inc.
CHASKA, Minn., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today...
Lifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment
19 déc. 2024 07h00 HE
|
Lifecore Biomedical, Inc.
Development Services Span Tech Transfer, Process Assessment and Method Validation for Fill and Finish of NRS-033 for Planned Phase 2 Trial Lifecore to Leverage Differentiated Capabilities and...
RTI Surgical Transforms into Evergen, a Leading CDMO in Regenerative Medicine
17 déc. 2024 08h00 HE
|
Evergen
ALACHUA, Fla., December 17, 2024 – RTI Surgical ("the Company"), a leading CDMO pushing the boundaries of innovation and tissue engineering to meet patient needs in regenerative medicine, today...
Global CMO/CDMO Market to Reach USD 38.87 Billion by 2032, Driven by Rising Demand for Outsourced Drug Manufacturing | Research by SNS Insider
12 déc. 2024 08h00 HE
|
SNS Insider pvt ltd
Austin, Dec. 12, 2024 (GLOBE NEWSWIRE) -- CMO/CDMO Market Size Analysis: “According to SNS Insider, the CMO/CDMO Market reached USD 23.32 billion in 2023 and is anticipated to grow up to USD 38.87...
Peptide and Oligonucleotide CDMO Market Trends and Growth Opportunities to 2030: Industry Forecast to Reach $5 Billion
12 déc. 2024 04h17 HE
|
Research and Markets
Dublin, Dec. 12, 2024 (GLOBE NEWSWIRE) -- The "Peptide and Oligonucleotide CDMO Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's...
Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2024
10 déc. 2024 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
CDMO Market Opportunities and Competitive Landscape Report 2024, with Profiles of Thermo Fisher Scientific, Merck, Lonza, Catalent and WuXi AppTec
29 nov. 2024 04h25 HE
|
Research and Markets
Dublin, Nov. 29, 2024 (GLOBE NEWSWIRE) -- The "CDMO Market Opportunities and Competitive Landscape" report has been added to ResearchAndMarkets.com's offering.The CDMO Market was valued at USD...
Lifecore Biomedical Amends and Extends Revolving Credit Facility with BMO
26 nov. 2024 16h05 HE
|
Lifecore Biomedical, Inc.
Three-Year Term Extension Combined with Simplification and Reduction of Interest Rates Helps Further Strengthen Company’s Balance Sheet and Overall Financial Position Builds Upon Other Recent...
RTI Surgical Announces First Patient Enrolled in Investigational Device Exemption (IDE) for Cortiva® Allograft Dermis in Breast Reconstruction
25 nov. 2024 07h00 HE
|
RTI Surgical
ALACHUA, Fla., November 25, 2024 – RTI Surgical ("RTI"), a leading CDMO pushing the boundaries of innovation and tissue engineering to address patient needs in regenerative medicine, today announced...
Lifecore Biomedical Hosts Virtual Investor Day
21 nov. 2024 16h17 HE
|
Lifecore Biomedical, Inc.
CHASKA, Minn., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today...